SMAD3 and melanoma: Briefly, as described in Figure 5a, Smad3 CRISPR-KO, Smad4 CRISPR-KO and control NT CRISPR-KO a375m melanoma cells were injected intravenously into NSG mice (tail vein injection; 8 mice/group).